CDIO (Cardio Diagnostics Holdings) Future Policy Benefits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDIO Cardio Diagnostics Holdings Inc CDIO
53 GF Score
Price $2.02
GF Value $1.80
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cardio Diagnostics Holdings Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.

CDIO
53GF Score
Cardio Diagnostics Holdings Inc CDIO
Future Policy Benefits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?

Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be overvalued. The current stock price of $2.02 is trading 12.4% above its estimated GF Value™ of $1.80. GuruFocus considers Cardio Diagnostics Holdings to be Modestly Overvalued.

Key valuation signals for CDIO:

  • Future Policy Benefits:
  • GF Value™: $1.80 vs. price of $2.02 (12.4% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardio Diagnostics Holdings Business Description

Address 311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
53GF Score

Get the complete analysis for CDIO

Future Policy Benefits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02
Price
$1.80
GF Value